Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Malaria
Interventions
BIOLOGICAL

CH-Alum50

intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)

BIOLOGICAL

CH-GLA2.5/50

intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)

BIOLOGICAL

TZ Ver

intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections

BIOLOGICAL

TZ Alum 50

intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)

BIOLOGICAL

TZ GLA 2.5/10

intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)

BIOLOGICAL

TZ GLA5/50

intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)

BIOLOGICAL

TZ GLA2.5/50

intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)

Trial Locations (2)

1011

CHUV CRC, Lausanne

Unknown

Bagamoyo Clinical Trial Unit (BCTU), Bagamoyo

All Listed Sponsors
collaborator

European Vaccine Initiative

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT01949909 - Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib | Biotech Hunter | Biotech Hunter